DONALD LYNN TRUMP
Medical Practice in Pittsburgh, PA

License number
Pennsylvania MX046368L
Category
Medicine
Type
Written Agreement
Address
Address
Pittsburgh, PA 15213

Personal information

See more information about DONALD LYNN TRUMP at radaris.com
Name
Address
Phone
Donald Trump, age 87
912 Scott Ave, Jeannette, PA 15644
(724) 413-0128
Donald Trump
540 E Lexington St, Allentown, PA 18103
Donald Trump
225 George St, Hanover, PA 17331
(717) 587-0967
Donald Trump, age 88
2034 Church View Rd, Coopersburg, PA 18036
(610) 509-2910
Donald M Trump
2034 Church View Rd, Coopersburg, PA 18036
(610) 967-5676

Professional information

Donald Trump Photo 1

Combination Chemotherapy

US Patent:
6559139, May 6, 2003
Filed:
Apr 6, 2000
Appl. No.:
09/544724
Inventors:
Candace S. Johnson - Pittsburgh PA
Donald L. Trump - Pittsburgh PA
Assignee:
University of Pittsburgh of the Commonwealth System of Higher Education - Pittsburgh PA
International Classification:
A61K 3159
US Classification:
514168, 514170, 514167, 514449, 514110, 514653
Abstract:
This invention relates to combination chemotherapy, particularly involving vitamin D or a derivative thereof. In one aspect, the invention provides a method of killing a cell by first administering to the cell vitamin D (or a derivative) and subsequently administering to the cell a cytotoxic agent. Where this strategy is applied to an intact tumor, the present invention provides a method of retarding the growth of the tumor by first administering vitamin D (or a derivative) to the tumor and subsequently administering the cytotoxic agent. A further aspect of the invention concerns a method of treating prostate cancer within a patient by co-administration of vitamin D (or a derivative) and a glucocorticoid to the patient. In yet a further aspect, the invention provides an improved method of treating a patient with vitamin-D involving the adjunctive administration of zoledronate.


Donald Trump Photo 2

Method For Identifying Altered Vitamin D Metabolism

US Patent:
2007020, Sep 6, 2007
Filed:
Jan 31, 2007
Appl. No.:
11/700462
Inventors:
Donald Trump - Pittsburgh PA, US
Josephia Muindi - Willamsville NY, US
Lionel Coignet - East Amherst NY, US
Candace Johnson - Amherst NY, US
International Classification:
C12Q 1/68, C12P 19/34
US Classification:
435006000, 435091200
Abstract:
A method is provided for identifying an individual as having altered vitamin D metabolism comprising analyzing a biological sample from the individual for the presence of CYP24 SNPs and/or aberrantly spliced CYP24 mRNA. The presence of the SNPs and/or the aberrantly spliced CYP24 mRNA indicates that the individual has altered vitamin D metabolism. Also provided are methods for customizing dosages of biologically active vitamin D compounds for individuals who are determined to have altered vitamin D metabolism.


Donald Trump Photo 3

Combination Chemotherapy

US Patent:
2003021, Nov 20, 2003
Filed:
May 5, 2003
Appl. No.:
10/429840
Inventors:
Candace Johnson - Pittsburgh PA, US
Donald Trump - Pittsburgh PA, US
Assignee:
University of Pittsburgh of the Commonwealth System of Higher Education - Pittsburgh PA
International Classification:
A61K033/24, A61K031/675, A61K031/704, A61K031/66, A61K031/56, A61K031/28
US Classification:
514/168000, 514/034000, 514/089000, 514/102000, 514/170000, 514/492000, 424/649000
Abstract:
This invention relates to combination chemotherapy, particularly involving vitamin D or a derivative thereof. In one aspect, the invention provides a method of killing a cell by first administering to the cell vitamin D (or a derivative) and subsequently administering to the cell a cytotoxic agent. Where this strategy is applied to an intact tumor, the present invention provides a method of retarding the growth of the tumor by first administering vitamin D (or a derivative) to the tumor and subsequently administering the cytotoxic agent. A further aspect of the invention concerns a method of treating prostate cancer within a patient by co-administration of vitamin D (or a derivative) and a glucocorticoid to the patient. In yet a further aspect, the invention provides an improved method of treating a patient with vitamin-D involving the adjunctive administration of zoledronate.


Donald Trump Photo 4

Endothelial Specific Targeting

US Patent:
6974791, Dec 13, 2005
Filed:
Mar 16, 2001
Appl. No.:
09/810700
Inventors:
Michael K. Wong - Wexford PA, US
Ruth A. Modzelewski - Glenshaw PA, US
Charles Komen Brown - Chicago IL, US
Candace S. Johnson - Pittsburgh PA, US
Donald L. Trump - Pittsburgh PA, US
Assignee:
The University of Pittsburgh - Pittsburgh PA
International Classification:
A61K038/00, A61K038/08, C07K007/00
US Classification:
514 2, 514 15, 530328
Abstract:
Peptide motifs which define specificity of tumor-derived endothelial cells. These peptides possess a charge motif of positive-positive-hydrophobic which is important in determining the specificity of binding to tumor-derived endothelium. The specific molecular peptide motifs will facilitate diverse therapeutic and diagnostic applications including: anti-angiogenic therapies to be used in alone or in conjunction with standard therapies; imaging tools for both detection of very small metastasis that are undetectable by current techniques; for monitoring tumor response; for targeting and directing chemotherapy drugs to the tumor; for treatment of chronic inflammatory diseases such as rheumatoid arthritis and psoriasis, for treating some forms of blindness; as well as other diagnostic and therapeutic applications.


Donald Trump Photo 5

Method For Identifying Altered Vitamin D Metabolism

US Patent:
2010007, Mar 25, 2010
Filed:
Jul 20, 2009
Appl. No.:
12/506025
Inventors:
Donald L. Trump - Pittsburgh PA, US
Josephia Muindi - Williamsville NY, US
Lionel J. Coignet - East Amherst NY, US
Candace S. Johnson - Amherst NY, US
International Classification:
C12Q 1/68
US Classification:
435 6
Abstract:
A method is provided for identifying an individual as having altered vitamin D metabolism comprising analyzing a biological sample from the individual for the presence of CYP24 SNPs and/or aberrantly spliced CYP24 mRNA. The presence of the SNPs and/or the aberrantly spliced CYP24 mRNA indicates that the individual has altered vitamin D metabolism. Also provided are methods for customizing dosages of biologically active vitamin D compounds for individuals who are determined to have altered vitamin D metabolism.


Donald Trump Photo 6

Combination Chemotherapy

US Patent:
2008000, Jan 3, 2008
Filed:
Jan 29, 2007
Appl. No.:
11/668330
Inventors:
Candace Johnson - Buffalo NY, US
Donald Trump - Pittsburgh PA, US
Assignee:
University of Pittsburgh of the Commonwealth System of Higher Education - Pittsburgh PA
International Classification:
A61K 31/59, A61K 33/24, A61P 35/00
US Classification:
424649000, 514167000
Abstract:
This invention relates to combination chemotherapy, particularly involving vitamin D or a derivative thereof hi one aspect, the invention provides a method of killing a cell by first administering to the cell vitamin D (or a derivative) and subsequently administering to the cell a cytotoxic agent. Where this strategy is applied to an intact tumor, the present invention provides a method of retarding the growth of the tumor by first administering vitamin D (or a derivative) to the tumor and subsequently administering the cytotoxic agent. A further aspect of the invention concerns a method of treating prostate cancer within a patient by co-administration of vitamin D (or a derivative) and a glucocorticoid to the patient. In yet a further aspect, the invention provides an improved method of treating a patient with vitamin-D involving the adjunctive administration of zoledronate.


Donald Trump Photo 7

Combination Chemotherapy

US Patent:
2003017, Sep 18, 2003
Filed:
Mar 17, 2003
Appl. No.:
10/390234
Inventors:
Candace Johnson - Pittsburgh PA, US
Donald Trump - Pittsburgh PA, US
Assignee:
University of Pittsburgh of the Commonwealth System of Higher Education - Pittsburgh PA
International Classification:
A61K031/675
US Classification:
514/168000, 514/094000
Abstract:
The invention provides a method of treating a patient with vitamin-D or a derivative thereof involving the adjunctive administration of zoledronate.